8-K: Profound Medical Highlights TULSA Procedure at SRS Meeting

Profound Medical Corp. announced its TULSA Procedure will be featured in multiple presentations at the Society of Robotic Surgery Annual Meeting.

Summary

• Profound Medical Corp. is participating in the Society of Robotic Surgery (SRS) Annual Meeting from July 23-26, 2026, in Fort Lauderdale, FL.
• The company's MRI-guided, AI-powered, Robotically-Driven and Incisionless TULSA Procedure for prostate cancer will be highlighted in several presentations by leading physicians.
• Key presentations will cover real-world outcomes, randomized controlled trials (CAPTAIN Trial), single-center efficacy and safety, intermediate-term oncologic and functional outcomes, and salvage procedures.
• Profound Medical's technology will also be spotlighted during the Society of Incisionless Surgery (SIS) plenary session, focusing on the integration of imaging, AI, and robotics in surgery.
• Company management will participate in an Investor Session on July 22, 2026, with medtech equity research analysts to discuss innovative robotic technologies and the TULSA-PRO platform.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive announcement due to the significant industry event participation and physician endorsements, highlighting technological advancements and market positioning.

Positives

• Significant presence at a major industry event (SRS Annual Meeting) showcasing the TULSA Procedure.
• Multiple presentations by leading physicians from prominent institutions (e.g., UT Southwestern Medical Center, National Medical Association and Research Group).
• Inclusion in the Society of Incisionless Surgery (SIS) plenary session, highlighting the company's role in shaping the future of surgery.
• Participation in an Investor Session with influential medtech equity research analysts from Stifel Financial and Wells Fargo.
• TULSA-PRO technology is highlighted for its combination of MRI guidance, AI, and robotic autonomy, enabling personalized treatment.
• The TULSA Procedure offers flexibility in treating prostate disease, from whole-gland ablation to focal therapy, potentially preserving quality of life.
• Profound Medical's technologies (TULSA-PRO and Sonalleve) are approved across major global markets, including FDA clearance in the US.

Negatives

• The filing is primarily an announcement of participation in a conference and does not contain new financial results or performance data.
• While the TULSA Procedure is highlighted, specific new clinical data or significant breakthroughs are not detailed in this announcement.
• The forward-looking statements section indicates potential risks and uncertainties that could affect the company's future performance.

Risks

• Risks associated with the medical device industry, including regulatory approvals and reimbursement challenges.
• Economic factors and general equity market conditions can impact the company.
• Risks associated with growth and competition in the medical device sector.
• The success of commercialization strategies for TULSA-PRO and Sonalleve is subject to various factors.
• Forward-looking statements may not occur as planned and could differ materially due to known and unknown risk factors.

Future Outlook

The company's future outlook is tied to the successful commercialization of its TULSA-PRO and Sonalleve platforms, advancements in MRI-guided therapy, and the expansion of its clinical applications. The company anticipates continued development and adoption of its technologies, subject to market and regulatory factors.

Management Comments

• "UT Southwestern has helped pioneer the TULSA Procedure for prostate cancer, having reached the 100th procedure milestone back in 2022, well before the CPT Category 1 codes became effective in January 2025. I am honored by this opportunity to share my experience, both as a surgeon and a researcher, at SRS2026."
• "Profound's TULSA-PRO represents a fundamentally different approach to traditional robotic surgery. By combining real-time MRI guidance, artificial intelligence, and supervised robotic autonomy, the platform enables surgeons to deliver highly personalized treatment based on each patient's unique anatomy and disease."
• "TULSA enables physicians to tailor treatment across a continuum of prostate disease, from whole-gland ablation to highly targeted focal therapy and everything in between. That flexibility allows us to personalize care while preserving quality of life whenever clinically appropriate. TULSA's AI empowers a smoother learning curve and wider adoption while maintaining excellent outcomes with increasing autonomy. I believe this represents the future of prostate disease treatment, and I am honored to share that vision with the distinguished researchers and clinicians attending SRS2026."
• "SRS2026 is a unique global industry event that encompasses all surgical specialties and robotic systems, linking top surgeons, researchers, engineers, and financial investors to accelerate robotic-assisted surgery. We are looking forward to sharing our story there."

Industry Context

StockSavvy.ai notes that Profound Medical's emphasis on MRI-guided, AI-powered, and robotic incisionless surgery aligns with the broader industry trend towards minimally invasive procedures, precision medicine, and the integration of artificial intelligence in healthcare. The company's participation in the SRS Annual Meeting and spotlight by the Society of Incisionless Surgery underscores its position in this evolving landscape.

Stakeholder Impact

• Shareholders: Potential for increased visibility and investor interest due to prominent industry event participation and positive physician commentary.
• Physicians/Clinicians: Opportunity to learn about and adopt advanced TULSA Procedure technology, potentially improving patient outcomes and treatment options.
• Patients: Access to innovative, less invasive treatment options for prostate disease, potentially leading to better quality of life and reduced side effects.
• Researchers: Platform for sharing data and advancing the understanding of MRI-guided, AI-powered surgical techniques.

Next Steps

• Presentations and discussions at the Society of Robotic Surgery (SRS) Annual Meeting (July 23-26, 2026).
• Participation in the Society of Incisionless Surgery (SIS) plenary session.
• Engagement with investors and analysts during the Investor Session (July 22, 2026).

Key Dates

Keywords

Profound Medical, TULSA Procedure, Robotic Surgery, MRI-guided, Incisionless Surgery, Prostate Cancer, Medical Device, SRS Annual Meeting